Potential targets on Sanofi’s radar
09/09/20 -"In line with its strategy of expanding its focus on the immuno-oncology space and strengthening its internal R&D pipeline, Sanofi has spent €5.2bn on the acquisition of two small biotech firms ..."
Pages
64
Language
English
Published on
09/09/20
You may also be interested by these reports :
25/02/26
While Q4 sales met the street’s expectations, H2 25 profitability somewhat exceeded the consensus. Most of the Q4 growth was driven by strong demand ...
23/02/26
Factoring in the SIFI acquisition (worth nearly 17% of Faes’ current market cap) and Faes Farma’s healthy (+16% topline growth in 9M 25) operating ...
20/02/26
After incorporating the 2025 financials, we have added a new forecast year to our model, which expects a continuation of growth at Novartis. The firm ...
20/02/26
Expanding margins despite moderate topline growth